UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 21,197 Shares of The Chemours Company (NYSE:CC)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC trimmed its holdings in shares of The Chemours Company (NYSE:CC) by 12.0% in the third quarter, according to its most recent filing with the SEC. The firm owned 155,278 shares of the specialty chemicals company’s stock after selling 21,197 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.10% of Chemours worth $3,155,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Matrix Trust Co bought a new position in shares of Chemours during the third quarter valued at $25,000. Blue Trust Inc. increased its position in shares of Chemours by 166.9% during the 3rd quarter. Blue Trust Inc. now owns 1,169 shares of the specialty chemicals company’s stock worth $26,000 after purchasing an additional 731 shares in the last quarter. Truvestments Capital LLC acquired a new stake in shares of Chemours during the 3rd quarter worth about $35,000. Brooklyn Investment Group bought a new position in Chemours during the 3rd quarter valued at about $37,000. Finally, Signaturefd LLC boosted its position in Chemours by 163.7% in the third quarter. Signaturefd LLC now owns 1,959 shares of the specialty chemicals company’s stock valued at $40,000 after buying an additional 1,216 shares in the last quarter. Institutional investors own 76.26% of the company’s stock.

Insider Activity at Chemours

In other Chemours news, SVP Alvenia Scarborough sold 7,500 shares of the business’s stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $20.64, for a total transaction of $154,800.00. Following the transaction, the senior vice president now owns 16,645 shares of the company’s stock, valued at $343,552.80. The trade was a 31.06 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.47% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the company. The Goldman Sachs Group cut their price objective on Chemours from $29.00 to $23.00 and set a “neutral” rating for the company in a research report on Tuesday, September 3rd. Barclays upped their price target on shares of Chemours from $21.00 to $23.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 5th. BMO Capital Markets raised their price objective on shares of Chemours from $30.00 to $32.00 and gave the company an “outperform” rating in a research report on Monday, October 7th. Royal Bank of Canada reiterated an “outperform” rating and set a $25.00 target price on shares of Chemours in a research report on Thursday. Finally, Morgan Stanley decreased their price target on shares of Chemours from $30.00 to $25.00 and set an “equal weight” rating on the stock in a research note on Tuesday, November 5th. Five analysts have rated the stock with a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $24.88.

Chemours Trading Down 1.8 %

NYSE:CC opened at $19.05 on Friday. The business’s 50-day simple moving average is $19.92 and its 200-day simple moving average is $20.84. The Chemours Company has a fifty-two week low of $15.10 and a fifty-two week high of $32.70. The company has a debt-to-equity ratio of 6.05, a current ratio of 1.73 and a quick ratio of 0.92. The stock has a market capitalization of $2.85 billion, a PE ratio of 38.09 and a beta of 1.80.

Chemours (NYSE:CC) last released its quarterly earnings results on Monday, November 4th. The specialty chemicals company reported $0.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.32 by $0.08. The firm had revenue of $1.50 billion for the quarter, compared to the consensus estimate of $1.44 billion. Chemours had a return on equity of 29.48% and a net margin of 1.34%. The company’s revenue for the quarter was up .9% on a year-over-year basis. During the same quarter last year, the business posted $0.64 EPS. Sell-side analysts expect that The Chemours Company will post 1.35 earnings per share for the current fiscal year.

Chemours Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, December 16th. Investors of record on Friday, November 15th will be given a dividend of $0.25 per share. The ex-dividend date is Friday, November 15th. This represents a $1.00 annualized dividend and a yield of 5.25%. Chemours’s dividend payout ratio (DPR) is presently 200.00%.

Chemours Profile

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.